Vascular effects of bisphosphonates-A systematic review

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 5, Issue , 2012, Pages 47-54

  Santos, Leyna L ^a   Cavalcanti, Taciana B ^a   Bandeira, Francisco A ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Aortic calcification; Atherosclerosis; Bisphosphonates; Carotid IMT; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; ETIDRONIC ACID; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING;

EID: 84868657503     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMED.S10007     Document Type: Review

References (45)

1. Desai MM, Zhang P, Hennessy CH. Surveillance for morbidity and mortality among older adults-United States, 1995-1996. MMWR CDC Surveill Summ. 1999;48:7-25.
2. Wayhs R, Zelinger A, Raggi P. High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol. 2002;39: 225-30.
3. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res. 1997;12:1761-8.
4. McFarlane SI, Muniyappa R, Shin JJ, et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004; 23:1-10.
5. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106:273-8.
6. Acierno LJ. Atherosclerosis (arteriosclerosis). In: Acierno LJ, editor. The History of Cardiology. New York, NY: Parthenon Publishing Group Inc; 1994:109-26.
7. Demer LL, Tintut Y. Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol. 2003;23:1739-43.
8. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-41.
9. Mautner GC, Mautner SL, Froehlich J, et al. Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation. Radiology. 1994;192:619-23.
10. Bostrom K, Demer LL. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr. 2000;10:151-8.
11. Vogt MT, San Valentin R, Forrest KY, et al. Bone mineral density and aortic calcification: the Study of Osteoporotic Fractures. J Am Geriatr Soc. 1997;45:140-5.
12. Frye MA, Melton LJ III, Bryant SC, et al. Osteoporosis and calcification of the aorta. Bone Miner. 1992;19:185-94.
13. Ouchi Y, Akishita M, de Souza AC, et al. Age-related loss of bone mass and aortic/aortic valve calcification-reevaluation of recommended dietary allowance of calcium in the elderly. Ann N Y Acad Sci. 1993;676: 297-307.
14. Van Der Klift M, Pols HA, Hak AE, et al. Bone mineral density and the risk of peripheral arterial disease: the Rotterdam study. Calcif Tissue Int. 2002;70:443-9.
15. Vogt MT, Cauley JA, Kuller LH, et al. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res. 1997;12:283-9.
16. Tankó LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int. 2003;73:15-20.
17. Montalcini T, Emanuele V, Ceravolo R, et al. Relation of low bone mineral density and carotid atherosclerosis in postmenopausal women. Am J Cardiol. 2004;94:266-9.
18. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med. 2003;19:395-414.
19. Papapoulos SE. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. Int J Clin Pract. 2003;57:417-22.
20. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19: 80-100.
21. Izutani H, Miyagawa S, Shirakura R, et al. Recipient macrophage deletion reduces the severity of graft coronary arteriosclerosis in the rat transplantation model. Transplant Proc. 1997;29:861-2.
22. Peller PJ, Ho VB, Kransdorf MJ. Extraosseous Tc-99m MDP uptake: a pathophysiologic approach. Radiographics. 1993;13:715-34.
23. Myers DT, Karvelis KC. Incidental detection of calcified dialysis graft on Tc-99m MDP bone scan. Clin Nucl Med. 1998;23:173-4.
24. Kim P, Turoglu T, Akisik MF, et al. Tc-99m MDP uptake in a calcified untreated non-Hodgkin's lymphoma of spleen. Clin Nucl Med. 1997;22: 343-4.
25. Ylitalo R, Monkkonen J, Urtti A, et al. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med. 1996;127:200-6.
26. Ylitalo R, Kalliovalkama J, Wu X, et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol. 1998;83:125-31.
27. Rosenblum IY, Flora L, Eisenstein R. The effect of disodium ethane-1- hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of atheroarteriosclerosis. Atherosclerosis. 1975;22:411-24.
28. Kramsch DM, Chan CT. The effect of agent interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res. 1978;42:562-71.
29. Kramsch DM, Aspen AJ, Rozler LJ. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science. 1981;213: 1511-2.
30. Ylitalo R, Oksala O, Yla-Herttuala S, et al. Effects of clodronate (dichloro-methylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med. 1994;123:769-76.
31. Zhu B-Q, Sun Y-P, Sievers RE, et al. Effects of etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed rabbits. Cardiology. 1994;85:370-7.
32. Daoud AS, Frank AS, Jarmolych J, et al. The effect of ethane- 1-hydroxy-1,1-d iphosphonate (EHDP) on necrosis of atherosclerotic lesions. Atherosclerosis. 1987;67:41-8.
33. Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int. 2006;70:1577-83.
34. Shioi A, Nishizawa Y, Jono S, et al. b-Glycerophosphonate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995;15:2003-9.
35. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibitartery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001;21:817-24.
36. Koshiyama H, Nakamura Y, Tanaka S, et al. Decrease in carotid intimamedia thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab. 2000;85:2793-6.
37. Celiloglu M, Aydin Y, Balci P, et al. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16(4):689-93.
38. Delibasi T, Emral R, Erdogan MF, et al. Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis. Adv Ther. 2007;24(2):319-25.
39. Kanazawa I, Yamaguchi T, Hayashi K, et al. Effects of treatment With risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010;339(6):519-24.
40. Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004;44(4):680-8.
41. Odate T, Ariyoshi T, Eishi K, et al. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Invest. 2006;26(4):215-22.
42. Kawahara T, Nishikawa M, Furusawa T, et al. Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging. J Atheroscler Thromb. 2011;18(5):384-95.
43. Hashiba H, Aizawa S, Tamura K, et al. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial. 2006;10(1):59-64.
44. Tankó LB, Qin G, Alexandersen P, et al. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int. 2005;16:184-90.
45. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharmacol. 2000;35: 287-96.